Decreased bone mineral density in neurofibromatosis type 1: Results from a pediatric cohort

Journal of Pediatric Orthopaedics

Volumn 27, Issue 4, 2007, Pages 472-475

  Dulai, Sukhdeep ^a   Briody, Julie ^b   Schindeler, Aaron ^b,c   North, Kathryn N ^c,d   Cowell, Christopher T ^b   Little, David G ^b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c University of Sydney   (Australia)

^d Institute for Neuromuscular Research   (Australia)

Author keywords

Bone mineral density; Neurofibromatosis type 1; NF1; Orthopaedics; Osteopenia; Osteoporosis; Pediatrics

Indexed keywords

AGE DISTRIBUTION; ARTICLE; BONE DENSITY; BONE MALFORMATION; CHILD; CLINICAL ARTICLE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FEMUR NECK; HEEL; HUMAN; LUMBAR SPINE; MALE; NEUROFIBROMATOSIS; OSTEOPENIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEX RATIO; ULTRASOUND;

ADOLESCENT; BONE DENSITY; BONE DISEASES, METABOLIC; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; FEMALE; FEMUR; FOLLOW-UP STUDIES; HEEL; HUMANS; INCIDENCE; LUMBAR VERTEBRAE; MALE; NEUROFIBROMATOSIS 1; PROGNOSIS; RISK FACTORS;

EID: 34249868715     PISSN: 02716798     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bpb.0000271310.87997.ae     Document Type: Article

References (20)

1. Young H, Hyman S, North K. Neurofibromatosis 1: clinical review and exceptions to the rules. J Child Neurol. 2002;17:613-621.
2. Friedman JM. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol. 2002;17:548-554.
3. Little DG, Dulai S, Williams P, et al. Early use of bisphosphonates in congenital pseudarthrosis of the tibia. Bone. 2004;34(suppl 1): S94-S95.
4. Illes T, Halmai V, de Jonge T, et al. Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int. 2001;12:823-827.
5. Kuorilehto T, Poyhonen M, Bloigu R, et al. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int. 2005;16:928-936.
6. Lammert M, Kappler M, Mautner VF, et al. Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int. 2005;16:1161-1166.
7. Lu PW, Briody JN, Ogle GD, et al. Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res. 1994;9:1451-1458.
8. Lu PW, Cowell CT, Lloyd-Jones SA, et al. Volumetric bone mineral density in normal subjects, aged 5-27 years. J Clin Endocrinol Metab. 1996;81:1586-1590.
9. Hogler W, Briody J, Woodhead HJ, et al. Importance of lean mass in the interpretation of total body densitometry in children and adolescents. J Pediatr. 2003;143:81-88.
10. Yap F, Hogler W, Briody J, et al. The skeletal phenotype of men with previous constitutional delay of puberty. J Clin Endocrinol Metab. 2004;89:4306-4311.
11. Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A. 1991;88:9658-9662.
12. DeClue JE, Cohen BD, Lowy DR. Identification and characterization of the neurofibromatosis type 1 protein product. Proc Natl Acad Sci U S A. 1991;88:9914-9918.
13. Costa RM, Silva AJ. Mouse models of neurofibromatosis type I: bridging the GAP. Trends Mol Med. 2003;9:19-23.
14. Klose A, Ahmadian MR, Schuelke M, et al. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum Mol Genet. 1998;7:1261-1268.
15. Yang FC, Chen S, Robling AG, et al. Hyperactivation of p21 and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest. 2006;1:2880-2891.
16. Miyazaki T, Katagiri H, Kanegae Y, et al. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol. 2000;148:333-342.
17. Nakamura H, Hirata A, Tsuji T, et al. Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res. 2003;18:1198-1205.
18. Nakayama K, Tamura Y, Suzawa M, et al. Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. J Bone Miner Res. 2003;18:827-835.
19. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature. 1997;389:618-622.
20. Wu X, Estwick SA, Chen S, et al. Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. Hum Mol Genet. 2006;15:2837-2845.